Patients in the canakinumab arm who achieved lower levels of high‐sensitivity C‐reactive protein (hs‐CRP) had improved outcome compared with those who did not achieve lower levels or those assigned to placebo, although only 20% of patients in CANTOS had a history of HF at baseline. This evidence concerns the gene CRP and hydrops fetalis.